Trident Labs, INC.
Trident Labs, INC. was paid $1.23M by Medicaid between Jan 2018 and Jul 2023, across 34 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 34% of everything it billed.
HOLLAND, MI 49424
Next to other Clinical Medical Laboratory providers in Michigan
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,719 | $222K | |
| 2019 | 5,515 | $401K | |
| 2020 | 7,717 | $456K | |
| 2021 | 1,394 | $92K | |
| 2022 | 866 | $44K | |
| 2023 | 356 | $19K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 34% | 4,057 | 3,889 | $415K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 29% | 3,333 | 3,056 | $362K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 20% | 7,529 | 6,981 | $250K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 8.3% | 1,640 | 1,467 | $102K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 4.3% | 1,154 | 1,125 | $52K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.4% | 271 | 267 | $18K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 118 | 77 | $7K |
| 80365 | <1% | 245 | 188 | $3K | |
| 80373 | <1% | 186 | 131 | $3K | |
| 80346 | <1% | 245 | 188 | $3K | |
| 80348 | <1% | 245 | 188 | $3K | |
| 80325 | <1% | 186 | 131 | $3K |
22 more codes
| 80369 | <1% | 245 | $3K | |
| 80361 | <1% | 245 | $3K | |
| 80353 | <1% | 245 | $3K | |
| 80358 | <1% | 245 | $3K | |
| 80354 | <1% | 244 | $3K | |
| 80349 | <1% | 244 | $3K | |
| 86769 | <1% | 12 | $337.04 | |
| 80356 | 0% | 59 | $0.00 | |
| 80372 | 0% | 59 | $0.00 | |
| 80323 | 0% | 59 | $0.00 | |
| 80321 | 0% | 59 | $0.00 | |
| 80342 | 0% | 59 | $0.00 | |
| 80355 | 0% | 59 | $0.00 | |
| 80360 | 0% | 59 | $0.00 | |
| 80366 | 0% | 59 | $0.00 | |
| 83992 | 0% | 59 | $0.00 | |
| 80324 | 0% | 52 | $0.00 | |
| 80368 | 0% | 59 | $0.00 | |
| 80335 | 0% | 59 | $0.00 | |
| 80363 | 0% | 59 | $0.00 | |
| 80359 | 0% | 59 | $0.00 | |
| 80345 | 0% | 59 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.